-transparent.png){kind=logo}
The effectiveness of intranasal neostigmine (9.3-13.8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
Related Publications
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
February 2018,
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
October 1983,
Journal of neurology, neurosurgery, and psychiatry,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
November 1955,
The American journal of medicine,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
January 1954,
Acta psychiatrica et neurologica Scandinavica,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
December 1948,
Annals of internal medicine,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
December 1993,
Clinical neuropharmacology,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
October 1962,
American journal of ophthalmology,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
July 1980,
Clinical pharmacology and therapeutics,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
January 1970,
Neurologia i neurochirurgia polska,
R Ricciardi, and
B Rossi, and
M Nicora, and
A Sghirlanzoni, and
A Muratorio
April 2004,
Muscle & nerve,
